Olesoxime

Olesoxime is an oral drug whose purpose is to reduce effects of oxidative stress on motor neurons. It was developed by a French patient organisation AFM in partnership with a French company Trophos. It was tested in type 2 and 3 SMA patients during 2011–2014, also in the UK, and the drug appeared to have promising effects. Many of those who were taking it reported increased muscle function and overall stabilisation of their condition.

The olesoxime programme was bought by Roche in 2015 with the purpose of commercialisation. Faced with technology hurdles and more effective compounds being increasingly available, Roche decided to stop olesoxime development in May 2018.

Clinical trials

Since early 2017, those who participated in the original Trophos trial, including a number of people with SMA from the UK, have been receiving olesoxime as a part of OLEOS clinical trial. After the trial’s 2018 closure all the participants have been given an option to transition to the Jewelfish clinical trial.

More information

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more